UNSPSC 51141573: Potassium bromide

This classification denotes an industrial aid with the molecular formula BR.K, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier OSD78555ZM. European Medicines Agency schedules potassium bromide in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB14970MIG. The term potassium bromide is a U.S. Pharmacopeial Convention designation. Most nations schedule potassium bromide under HS 28275100 and SITC 52329. As of Q4 2014, POTASSIUM BROMIDE remains the US FDA Preferred Term for this commodity.

Potassium bromide bears US NLM identifiers UMLS ID C0071754 and NCI Concept Code C76725. SMILES: [K+].[Br-].

UNSPSC 51141573 Potassium bromide is a Commodity code under which state and local governments have recently procured pharmaceuticals and pharmaceutical products, though the recent opportunities tagged to this code diverge substantially from potassium bromide's chemical identity and instead reflect broader pharmaceutical procurement. Seminole County, Florida issued IFB 60459723LAS in June 2026 to procure naloxone and drug deactivation systems through annual competitive bidding; the Texas Health and Human Services Commission posted RFI HHS0017013 in April 2026 to explore vendor capabilities for a direct-to-manufacturer pharmacy prescription program; and the Minnesota Multistate Cooperative Purchasing Alliance (MMCAP), administered by the Minnesota Department of Administration's Office of State Procurement, released RFP S1070000015802 in January 2026 to establish statewide contracts for generic multi-source pharmaceuticals and over-the-counter products available through authorized wholesalers. The issuing bodies comprise county public health departments, state health agencies, and cooperative purchasing vehicles serving multiple jurisdictions. The actual procurement activity documented here centers on pharmaceutical supply agreements, naloxone distribution, and generic drug contracting rather than potassium bromide specifically, indicating either a tagging mismatch or a substantially broader scope in practice than the Commodity code name suggests.

Recent activity spans Florida, Texas, and Minnesota, with the MMCAP cooperative extending to participating state and local governments including Oregon. The Seminole County naloxone procurement (IFB, response deadline July 26, 2023) required 1,900 units of naloxone and 800 safe drug deactivation systems annually with quarterly deliveries, full vendor responsibility for shipping, E-Verify compliance, and a two-year term with one-year renewal option. The Texas HHS RFI (response deadline April 3, 2026) represents exploratory market intelligence on direct-to-manufacturer prescription relationships outside traditional pharmacy benefit manager and wholesaler channels. The MMCAP RFP (proposals due March 26, 2026) established multi-award contracts for generic pharmaceuticals and OTC products through three authorized wholesalers—AmerisourceBergen (Cencsa), Cardinal Health, and Morris & Dickson—with NDC-level product specification, cGMP and DSCSA compliance certification, and evaluation weighted 75 percent on price competitiveness. Vendors faced a 3 percent administrative fee, $5 million commercial general liability insurance requirement, and performance penalties of $200 to $1,500 per reportable violation. The disconnect between the Commodity code name and the pharmaceutical-supply nature of recent opportunities warrants verification of whether this code is the appropriate classification for pharmaceutical procurement activity in your target markets.